Rapid Plasma Reagin in Serum
NHANES 2003–2004
1. SUMMARY OF TEST PRINCIPLE AND CLINICAL RELEVANCE
The rapid plasma reagin (RPR) 18-mm circle card test is a macroscopic, nontreponemal flocculation card
test used to screen for syphilis (1–4). The antigen is prepared from a modified Venereal Disease Research
Laboratory (VDRL) antigen suspension containing choline chloride to eliminate the need to heat-inactivate
serum, ethylenediaminetetraacetic acid (EDTA) to enhance the stability of the suspension, and finely
divided charcoal particles as a visualizing agent. In the test, the RPR antigen is mixed with unheated or
heated serum or with unheated plasma on a plastic-coated card. The RPR test measures IgM and IgG
antibodies to lipoidal material released from damaged host cells as well as to lipoprotein-like material, and
possibly cardiolipin released from the treponemes (5, 6). The anti-lipoidal antibodies are antibodies that are
produced not only as a consequence of syphilis and other treponemal diseases, but also in response to
nontreponemal diseases of an acute and chronic nature in which tissue damage occurs (7). If antibodies are
present, they combine with the lipid particles of the antigen, causing them to agglutinate. The charcoal
particles coagglutinate with the antibodies and show up as black clumps against the white card. If antibodies
are not present, the test mixture is uniformly gray. The test can be purchased in kit form or in component
parts from many commercial sources. Without some other evidence for the diagnosis of syphilis, a reactive
nontreponemal test does not confirm T. pallidum infection.
2. SAFETY PRECAUTIONS
The risk of infection due to an occupational exposure to blood depends upon the prevalence of blood-borne
pathogens in the population supplying the blood specimens, the probability of infection given a particular
type of exposure to a blood-borne pathogen, and the frequency of exposures (9, 10).
T. pallidum is present in circulating blood during primary and secondary syphilis. The minimum number
(LD50) of T. pallidum organisms needed to infect by subcutaneous injection is 23 (11). The concentration of
T. pallidum in patients' blood during early syphilis, however, has not been determined. The ability of blood
inoculated with T. pallidum to infect animals is reduced by refrigerated storage (12, 13). Although multiple
instances of transmission of T. pallidum due to transfusion of an infected donor's blood were reported prior
to the introduction of penicillin for treatment of syphilis and of refrigeration for blood storage (12).
Subsequent reports have been rare (12, 13). Infection of a health care or laboratory worker following
exposure to T. pallidum-infected blood has, apparently, not been reported.
Authoritative sources focus attention on infection with hepatitis B virus (HBV), hepatitis C virus (HCV), and
human immunodeficiency virus (HIV) as the principal concerns associated with exposure to blood (10, 15–
18). The prevalence of these infections varies greatly among patient populations tested for T. pallidum
infection. HBV infection is most common. HBV viremia is indicated by tests for HBV surface antigen
(HBsAg) in serum. Prevalence of anti-HBsAg, from published studies of patients in hospitals and emergency
rooms cited in a recent review, ranged from 0.9 to 6% (9, 19–22). Unlike initial HBV infection, in which only
a minority of individuals continues to be viremic, initial HCV and HIV infections lead to persistent viremia in
most individuals. Consequently, serum antibody to HCV and HIV are indicators of potential infectiousness.
Seroprevalences of antibody to HCV in studies of patients in hospitals and emergency rooms cited in a
recent review ranged from 2 to 18% (18, 21-24). HIV prevalence ranged from 0.1 to 5.6% in patients
enrolled in a national hospital surveillance system (9, 25). All three infections are more common among
patients at increased risk for syphilis, especially patients with a history of illegal drug use. For example,
seroprevalences of antibody to HCV were 10% among non-drug-using attendees at sexually transmitted
diseases clinics and 60% among injection-drug users (26–28).
Infections with HBV (27, 29) and HIV (17, 30–32) can occur with skin and mucus membrane exposures to
blood; however, needle-stick and percutaneous injury with blood-coated sharp objects are the principal
sources of laboratory-associated acquisition of these agents. The risk of infection following exposure to
blood from an infected patient is greatest for HBV, except for exposed individuals who are immune due to
prior HBV infection or vaccination. The risk is highest if the source individual is HBSAG-positive (27, 33–35)
and is positive for envelope (E) antigen. A vaccine to prevent HBV infection has been available since 1982
and is strongly recommended for health care workers with potential exposures to blood or other body fluids
(33, 36, 37). Individuals with anti-HBV antibody from vaccination or prior infection are considered to be
immune to HBV infection.
Page 3 of 14